2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Diodes reported second quarter 2026 revenue of $445.5 million, up 22% from a year earlier, and GAAP net income of $46.6 million, or $1.00 per diluted share, compared with $0.99 a year earlier. The company guided third quarter revenue to about $510 million plus or minus 3%, and said it has proposed acquiring ElevATE Semiconductor, a maker of automated test equipment chips.
Q2 2026 revenue was $445.5 million, up 22% from $366.2 million a year earlier and up 10% from $405.5 million in Q1 2026.
GAAP net income was $46.6 million, or $1.00 per diluted share, versus $46.1 million, or $0.99, a year earlier; non-GAAP adjusted EPS was $0.70 versus $0.32.
Q3 2026 guidance: revenue of about $510 million plus or minus 3%, GAAP gross margin of 35% plus or minus 1%, and non-GAAP adjusted EPS of $1.05 plus or minus $0.10.
Management expects the proposed ElevATE Semiconductor acquisition to add about $50 million of revenue in the first 12 months after closing.
Inuvo reported second-quarter 2026 net revenue of $7.5 million, down 67% from a year earlier, as Legacy Search revenue fell 80% and Audience Modeling revenue rose 19%. The net loss widened to $4.0 million, or $0.27 per share, from $1.5 million, or $0.10 per share, and the company said CFO Wallace D. Ruiz will retire effective August 17, 2026, with Derric Ciccone succeeding him. For shareholders, the revenue base is much smaller, losses are larger, and the finance leadership is changing.
Net revenue was $7.5 million in Q2 2026, down 67%; Legacy Search revenue fell 80% and Audience Modeling revenue rose 19%.
Net loss was $4.0 million, or $0.27 per share, versus a net loss of $1.5 million, or $0.10 per share, in Q2 2025.
Wallace D. Ruiz retires as CFO and Secretary effective August 17, 2026; Derric Ciccone is appointed President, CFO and Secretary effective the same day.
The company completed financing of about $13 million in gross proceeds; cash and cash equivalents were $886 thousand at June 30, 2026, plus $6.2 million in restricted cash.
B&G Foods said its President and CEO Casey Keller retired effective August 7, 2026, and its board appointed director Robert D. Mills as President and CEO effective August 10, 2026. Mills, previously a senior executive at Tractor Supply Company, will leave the board's nominating and governance committee because he is no longer an independent director under NYSE standards.
Keller retired as President, CEO and director effective August 7, 2026; his retirement agreement includes salary continuation payments of $2,448,516 and accelerated vesting of 519,396 restricted shares.
Robert D. Mills, age 53 and a board member since 2018, took over as President and CEO on August 10, 2026.
Mills's employment agreement sets a $950,000 base salary, a $500,000 sign-on bonus payable after March 31, 2027, and a stock option grant for 900,000 shares at $3.40.
Mills previously held senior roles at Tractor Supply Company from 2014 to August 2026, most recently as Executive Vice President, Chief Technology Officer, Digital and Pet Services.
Powerfleet, Inc. appointed Paul Lalljie as President and Chief Financial Officer effective August 11, 2026, after terminating CFO David Wilson's employment as of the close of business on August 10, 2026. The filing sets out Lalljie's pay package and Wilson's separation and consulting terms, which matter to shareholders because they reflect a change in the company's top finance role.
Lalljie receives a $475,000 base salary, a bonus of up to 85% of salary, a $100,000 sign-on bonus, and 225,000 time-based RSUs plus a 225,000-unit performance RSU target.
Lalljie previously served as CFO and later CEO of 2U, Inc. from 2019 to 2024, and spent about 18 years at Neustar, Inc., including nearly a decade as CFO.
Wilson receives a $224,460 lump-sum severance, a $121,731.65 pro-rated bonus payment, and COBRA reimbursement through February 28, 2027.
Wilson will also serve as a consultant at $37,410 per month for an initial 90-day term, with renewals.
Matthews International's Board appointed Michael J. Whitehead as President and Chief Executive Officer and as a director, effective August 31, 2026, succeeding Joseph C. Bartolacci, who is retiring. Whitehead most recently served as Executive Vice President and President, Americas Welding, at Lincoln Electric Holdings, and the filing sets out his base salary, transition payment, incentive awards and severance terms, which shareholders can review.
Whitehead becomes CEO and director effective August 31, 2026; Bartolacci told the company of his retirement decision on July 29, 2026.
Initial base salary of $1,000,000 per year, plus a one-time transition cash payment of $300,000 that he must repay if he resigns or is terminated for cause within 12 months.
Target annual bonus of 100% of base salary from fiscal 2027; long-term incentive grant date value of $3,675,000 plus a one-time restricted stock unit award of $1,600,000.
If terminated without cause, severance of 24 months of base salary continuation plus a bonus at 100% of target.
Femasys Inc. closed a private placement on August 10, 2026, expected to bring in approximately $30.0 million in gross proceeds before offering expenses. The deal included common stock priced at $3.20 per share, plus warrants that could dilute existing holders, and gave the lead investor Nantahala Capital Management rights to appoint up to two board designees.
Purchase agreement dated August 7, 2026; closing occurred August 10, 2026, with expected gross proceeds of approximately $30.0 million
Common stock sold at $3.20 per share; 5,013,559 common shares and 4,361,440 pre-funded warrants issued, plus 18,749,998 accompanying warrants
Warrants exercisable at $2.95 per share; Milestone Warrants require U.S. revenue of at least $1,500,000 in a fiscal quarter and a stock price condition
Five company insiders, including the CEO and CFO, bought securities for an aggregate of approximately $134,000; resale registration statement due within 30 days of closing
NRC Health's Chief Financial Officer, Shane Harrison, resigned on August 7, 2026 to pursue an outside professional opportunity, effective August 28, 2026. The company has started a search for a new CFO, so shareholders will see a change in the officer who leads financial reporting.
Shane Harrison, Chief Financial Officer and principal financial officer, tendered his resignation on August 7, 2026.
Resignation is effective August 28, 2026.
Reason given: to pursue an outside professional opportunity.
The company has initiated a search for a new Chief Financial Officer.
Hyliion reported second-quarter 2026 revenue of $4.9 million, up from $1.5 million a year earlier, and a net loss of $13.9 million, compared with $13.4 million in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to approximately $15 million from $10 million, while the wider net loss and continued cash use leave profitability further out of reach for shareholders.
Q2 2026 revenue was $4.9 million versus $1.5 million in Q2 2025; net loss was $13.9 million versus $13.4 million.
Full-year 2026 revenue guidance raised to approximately $15 million from $10 million.
Cash and investments were $132.4 million at June 30, 2026; year-end 2026 outlook is $115 million to $120 million, up from about $100 million.
The company cited a $41.7 million U.S. Navy contract awarded in the quarter.
Lumentum reported fourth-quarter fiscal 2026 net revenue of $1.01 billion, up from $480.7 million a year earlier, but a $7.8 billion non-cash loss on debt extinguishment from equitizing convertible notes drove a GAAP net loss of $7.2 billion, or $84.65 per diluted share. The company guided first-quarter fiscal 2027 net revenue to $1.225 billion to $1.275 billion, with non-GAAP diluted EPS of $4.05 to $4.35.
Q4 fiscal 2026 net revenue was $1.01 billion, up 109.3% year over year and 24.5% from the third quarter's $808.4 million.
Q4 GAAP net loss was $7.2 billion ($84.65 per diluted share), driven by a one-time, non-cash loss on debt extinguishment of $7.8 billion.
Q4 non-GAAP net income was $326.3 million, or $3.23 per diluted share, versus $0.88 a year earlier.
Q1 fiscal 2027 guidance: net revenue of $1.225 billion to $1.275 billion and non-GAAP operating margin of 39.5% to 40.5%.
Kilroy Realty Corporation said Chief Financial Officer Jeffrey Kuehling is leaving the company effective August 11, 2026, and that Chief Investment Officer Eliott Trencher will serve as interim CFO and Treasurer. The company is conducting an external search for a permanent principal financial officer. It also reaffirmed its 2026 guidance from its July 27, 2026 second-quarter earnings release and said the departure involved no disagreements over financial policies, accounting principles, financial statements or disclosures.
Jeffrey Kuehling, EVP, CFO and Treasurer, is leaving effective August 11, 2026; the filing describes this as a termination without Cause under his July 30, 2024 Employment Agreement.
Kuehling will receive the severance payments and benefits under Section 5.3(b) of his employment agreement plus two months of severance pay, subject to a release of claims becoming effective. The filing gives no dollar amounts.
Eliott Trencher, age 43, is interim CFO and Treasurer and also keeps his role as EVP and Chief Investment Officer; he was CFO from February 2022 to August 2024.
The company reaffirmed its 2026 guidance from the July 27, 2026 second-quarter 2026 earnings release and has engaged Russell Reynolds Associates for the executive search.
Astronics reported second-quarter 2026 sales of $260.0 million, up 27.0% from a year earlier, and net income of $35.1 million, or $0.75 per diluted share, compared with $0.03 per diluted share in the prior-year quarter. The company raised its 2026 revenue forecast to $1.02 billion to $1.04 billion, which signals higher expected sales for shareholders.
Q2 2026 sales rose 27.0% to $260.0 million; operating income was $40.5 million, or 15.6% of sales.
Net income was $35.1 million, or $0.75 per diluted share, versus $1.3 million, or $0.03 per diluted share, a year earlier.
Bookings were $306.2 million for a 1.18 book-to-bill ratio, and backlog reached $780.6 million at July 4, 2026.
Third-quarter 2026 sales are expected to be $265 million to $275 million.
ERock reported second-quarter 2026 total revenues of $39.9 million, down 41.7% from $68.5 million a year earlier, and a net loss of $67.7 million versus $8.0 million in the prior-year quarter. The company also initiated full-year 2026 guidance of $435 million to $465 million in revenue and $3 million to $9 million in Adjusted EBITDA, and said contracted backlog rose to about $1.7 billion, which it expects to convert into higher second-half deliveries.
Q2 2026 total revenues were $39.9 million, versus $68.5 million in Q2 2025; Adjusted EBITDA was negative $14.0 million, versus positive $3.6 million a year earlier
Net loss was $67.7 million in Q2 2026, including a $48.8 million loss on debt extinguishment
Full-year 2026 guidance: revenue of $435 million to $465 million and Adjusted EBITDA of $3 million to $9 million
Contracted Power System Sales Backlog was about $1.7 billion at June 30, 2026, up from about $0.2 billion a year earlier; cash was $626.6 million with no outstanding debt
Owlet reported second-quarter 2026 revenue of $33.9 million, up 29.9% from a year earlier, and a net loss of $0.6 million, compared with $37.4 million in the second quarter of 2025. Results include a one-time $3.75 million tariff refund benefit to Adjusted EBITDA, and the company raised its 2026 gross margin and Adjusted EBITDA outlook while leaving its revenue outlook unchanged. The company also said it will revise prior-period financial statements to correct stock-based compensation errors.
Q2 2026 revenue was $33.9 million, up from $26.1 million in Q2 2025; subscription revenue was $3.2 million, up $2.4 million.
Q2 2026 net loss was $0.6 million, versus $37.4 million a year earlier; excluding the $3.75 million tariff refund impact, the net loss was $4.4 million.
2026 Adjusted EBITDA outlook raised to $10.75 to $12.75 million from $7 to $9 million; the company said the increase reflects only the one-time $3.75 million refund.
Prior-period financial statements, including the quarter ended March 31, 2026, will be revised for stock-based compensation errors in the Form 10-Q expected by August 14, 2026.
374Water released preliminary second-quarter 2026 revenue of more than $2.2 million, compared with $0.6 million a year earlier, and said first-half revenue was about $2.8 million versus $1.1 million. The company said about $2.0 million of the quarter's revenue came after the Orange County Sanitation District Factory Acceptance Test, and it named Charles Weiser as Chief Financial Officer. Full second-quarter results are due August 14, 2026.
Preliminary Q2 2026 revenue exceeded $2.2 million, versus $0.6 million in Q2 2025, with about $2.0 million tied to the OC San Factory Acceptance Test.
Preliminary first-half 2026 revenue was about $2.8 million, versus $1.1 million in the first half of 2025.
Charles Weiser, CPA, was appointed Chief Financial Officer, succeeding interim CFO Adrienne Anderson.
The company will release complete second-quarter financial results on August 14, 2026.
ConocoPhillips said its board elected Andy O'Brien, currently executive vice president and chief financial officer, as president and chief executive officer effective September 1, 2026, succeeding Ryan Lance, who will retire as CEO and become executive chair. Konnie Haynes-Welsh will become chief financial officer on the same date, and the filing lists new pay terms for the leadership changes.
Andy O'Brien becomes president and CEO and joins the board on September 1, 2026, with a base salary of $1.7 million and a long-term incentive target of $13.08 million.
Ryan Lance's base salary as executive chair will fall to $1.1 million, and he will not participate in the annual incentive plan; his 2027 long-term incentive target is $12.4 million.
Konnie Haynes-Welsh becomes senior vice president and chief financial officer, with an annual base salary of $742,972.
Ferguson Enterprises entered into a $700 million bridge credit facility and a $900 million term loan facility, both with JPMorgan Chase Bank as administrative agent, to help fund its acquisition of FWI Holdings, Inc. (FloWorks). The bridge loan is available only if the company lacks other bank or capital markets financing sufficient to fund the deal, and both facilities depend on the acquisition closing.
Bridge credit facility of up to $700 million, unsecured, maturing 364 days after funding
Term loan facility of up to $900 million, unsecured, maturing three years after funding
Both facilities require a maximum net leverage ratio of 3.50 to 1.00, stepping up to 4.00 to 1.00 after certain material acquisitions
TransAct reported preliminary second-quarter 2026 net sales of $13.9 million, up 1% from a year earlier, and a net loss of $50 thousand, narrower than the $143 thousand loss in the prior-year quarter. The company raised its 2026 adjusted EBITDA guidance to $1.5 million to $2.0 million and kept its net sales outlook at $55 million to $57 million, while its board began a formal strategic review of the Casino and Gaming business with BofA Securities as financial advisor and no set timetable. The filing also discloses a severance agreement with CFO Troy W. Ingianni.
Net sales were $13.9 million versus $13.8 million a year earlier; Casino and Gaming sales fell 4% to $7.3 million, including a $1.0 million reduction from tariff surcharge refunds.
Net loss was $50 thousand, or $0.00 per diluted share, versus a $143 thousand loss, or $(0.01) per share, in Q2 2025; adjusted EBITDA was $514 thousand versus $478 thousand.
2026 guidance: net sales of $55 million to $57 million (reiterated); adjusted EBITDA of $1.5 million to $2.0 million (raised).
The board launched a formal strategic review of Casino and Gaming with BofA Securities, with no timetable or assurance of a transaction; a CFO severance agreement dated August 10, 2026 was also filed.
Silicon Labs reported second-quarter 2026 revenue of $228 million, up 18% from a year earlier, and its GAAP net loss narrowed to $10.6 million from $21.8 million. Non-GAAP diluted earnings per share were $0.71, and the company suspended forward-looking guidance because of its pending acquisition by Texas Instruments.
Revenue was $228 million, up 18% year-over-year; Industrial & Commercial revenue was $135 million and Home & Life revenue was $93 million.
GAAP diluted loss per share was $(0.32), compared with $(0.67) a year earlier; GAAP operating loss was $11 million.
Non-GAAP diluted earnings per share were $0.71, up 545% year-over-year; GAAP gross margin was 61.6%.
Silicon Labs has suspended forward-looking guidance due to the announced pending acquisition by Texas Instruments.
National CineMedia reported fiscal second quarter 2026 revenue of $58.4 million, up 12.7%, while its operating loss widened and its net loss narrowed to $9.9 million. The company also agreed on August 10, 2026 to acquire Captivate Holdings for an enterprise value of $275.0 million, paused its quarterly dividend, and gave no forward outlook, which matters to shareholders because it adds significant debt and removes near-term guidance.
Q2 revenue rose 12.7% to $58.4 million from $51.8 million; operating loss widened to $12.8 million from $12.0 million.
Net loss narrowed to $9.9 million, or $0.11 per diluted share, from $10.7 million, or $0.11 per diluted share, a year earlier.
Captivate acquisition: enterprise value of $275.0 million, funded by $275.0 million of new committed term debt; expected to close in the second half of 2026.
Quarterly dividend paused due to the proposed acquisition and expected leverage at closing; no forward outlook provided.
Comscore said it will reduce its workforce and other corporate costs under a realignment plan authorized by its board on August 6, 2026, with estimated one-time costs of $7 million to $9 million. The company expects $20 million to $25 million in annual run-rate cost savings, and its CEO and CFO agreed to salary cuts and other pay changes, while the chief commercial officer will move to an advisory role until December 1, 2026. For shareholders, the expected savings must be weighed against the one-time charges and the risk that execution costs or unintended effects exceed expectations.
The realignment plan was authorized by the board on August 6, 2026 and announced on August 11, 2026.
Estimated one-time costs are $7 million to $9 million, including $6 million to $8 million in cash severance and termination benefits.
Expected annual run-rate cost savings are $20 million to $25 million, with implementation substantially complete in the third quarter of 2027.
CEO Matt McLaughlin's base salary falls from $625,000 to $500,000 effective October 1, 2026; CFO Mary Margaret Curry's falls 10% to $360,000.
H&R Block reported fiscal 2026 results for the year ended June 30, 2026, with revenue of $3.95 billion, up 4.9%, and GAAP earnings per share from continuing operations of $5.69, up 28.7%. The GAAP figure includes a one-time $0.65 per share tax benefit tied to an IRS examination resolution, while adjusted earnings per share rose 13.9% to $5.31. The board raised the quarterly dividend 10% to $0.46 per share and set fiscal 2027 adjusted diluted EPS guidance of $6.04 to $6.24.
Revenue of $3.95 billion rose $184.4 million, or 4.9%; operating expenses of $3.0 billion rose 3.6%.
Net income from continuing operations was $736.3 million, up 20.8%; the $84.1 million one-time tax benefit added $0.65 to EPS.
Quarterly dividend increased 10% to $0.46 per share, payable October 6, 2026, to holders of record as of September 3, 2026.
Fiscal 2027 outlook: revenue of $4.11 to $4.16 billion and adjusted diluted EPS of $6.04 to $6.24.
National CineMedia's subsidiary agreed on August 10, 2026 to acquire Captivate Holdings, LLC, a digital video elevator and lobby advertising operator, for an enterprise value of $275.0 million, funded with new committed term debt. The company said it is pausing its dividend and share repurchase programs so free cash flow can go toward debt reduction, and it expects closing in the second half of 2026.
Enterprise value of $275.0 million, payable in cash, subject to customary purchase price adjustments; the Company guaranteed the Buyer's obligations
Financing: $275.0 million senior secured term loan and $25.0 million revolving facility, with a maximum Total Net Leverage Ratio of 5.00:1.00 stepping down over time; the company expects net leverage of approximately 3.9x at close
Captivate's 2025 revenue was approximately $64 million and Adjusted EBITDA approximately $19 million, according to the press release
Dividend and share repurchase programs are paused; closing is expected in the second half of 2026, subject to conditions including HSR waiting period expiration
Griffon Corporation agreed on August 10, 2026 to sell $800 million of 6.25% senior notes due 2034 to initial purchasers led by BofA Securities. The company said it intends to use the net proceeds to redeem all of its outstanding 5.750% senior notes due 2028, plus pay related fees, premiums and accrued interest. The filing does not state the effect on interest expense or leverage.
Principal amount: $800 million of 6.250% senior notes due 2034, guaranteed by subsidiaries
Purpose: redeem all outstanding 5.750% senior notes due 2028 and pay related fees and expenses
Agreement dated August 10, 2026; press release on pricing issued the same day
Notes sold without SEC registration, under exemptions from the Securities Act of 1933
GrowGeneration reported second-quarter 2026 net sales of $43.2 million, up 5.5% from a year earlier, and a GAAP net loss of $2.0 million, down from $4.8 million. The company reaffirmed its full-year 2026 net revenue range of $162 million to $168 million and raised its full-year Adjusted EBITDA outlook to $2 million to $3 million. For shareholders, sales and profit both improved, and the company's Adjusted EBITDA outlook is now higher.
Q2 2026 net sales were $43.2 million, up from $41.0 million in Q2 2025; the company said this was its third straight quarter of year-over-year revenue growth
GAAP net loss narrowed to $2.0 million from $4.8 million; Adjusted EBITDA was a gain of $0.3 million versus a loss of $1.3 million a year earlier
Full-year 2026 net revenue guidance of $162 million to $168 million was reaffirmed; Adjusted EBITDA guidance is $2 million to $3 million
Third-quarter 2026 net sales are expected to be $44 million to $46 million; cash and marketable securities were $41.0 million at June 30, 2026, with no debt
Evolv Technologies reported second-quarter 2026 revenue of $43.8 million, up 34% from a year earlier, and a net loss of $9.3 million, down from $40.5 million in the same quarter of 2025. The company raised its 2026 total revenue forecast to $180 million to $185 million, from $175 million to $180 million, which signals stronger expected sales for shareholders.
Q2 2026 revenue was $43.8 million, up 34% from $32.5 million in Q2 2025.
Ending annual recurring revenue was $132.7 million at June 30, 2026, up 20% year over year.
Q2 2026 net loss was $9.3 million, or $(0.05) per share, versus $40.5 million, or $(0.25) per share, a year earlier.
2026 revenue outlook was raised to $180 million-$185 million; year-end ARR outlook is $148 million-$150 million.
NeuroPace reported second quarter 2026 revenue of $22.8 million, up 17% from $19.5 million a year earlier, and its net loss narrowed to $6.2 million from $10.0 million. The company raised its full-year 2026 total revenue guidance and its Adjusted EBITDA loss outlook, which may matter to shareholders because it signals stronger expected sales and a smaller expected loss for the year.
Q2 2026 total revenue was $22.8 million, up 17% from $19.5 million in Q2 2025; RNS System revenue rose 21.3% to $22.5 million.
Q2 2026 net loss was $6.2 million, compared with $10.0 million in Q2 2025 (continuing operations).
Full-year 2026 total revenue guidance was raised to $99.5 million to $101.5 million from $99 million to $101 million.
Full-year 2026 Adjusted EBITDA guidance was raised to a loss of $7.5 million to $8.5 million from a loss of $8.5 million to $9.5 million.
Energy Vault reported second-quarter 2026 revenue of $17.4 million, up 104% from a year earlier, and a GAAP net loss of $29.7 million, narrower than the $34.9 million loss in the prior-year quarter. The company raised its full-year 2026 revenue guidance to $270-310 million from $225-300 million and narrowed its GAAP gross margin guidance to 20-25% from 15-25%, which points to a stronger outlook for shareholders, though the company still reports losses and its adjusted EBITDA loss widened.
Q2 2026 revenue was $17.4 million, up from $8.5 million in Q2 2025, and GAAP gross margin was 31.0% versus 29.6%.
GAAP net loss was $29.7 million, or $(0.17) per share, compared with $34.9 million, or $(0.22) per share, a year earlier; adjusted EBITDA loss was $17.0 million versus $13.6 million.
Backlog reached about $2 billion as of August 10, 2026, up about 107% year over year, including a 1.25 GW contract expected to generate $500-600 million of revenue in the second half of 2026 and 2027.
Cash and cash equivalents, including restricted cash, were $148 million as of June 30, 2026; the company targets $160-200 million in total cash at year-end 2026.
Supermicro reported unaudited results for the fourth quarter and full fiscal year ended June 30, 2026, with Q4 net sales of $11.1 billion, up from $5.8 billion a year earlier, and Q4 net income of $1,178 million, up from $195 million. The company guided first-quarter fiscal 2027 net sales to $14.5 billion to $15.5 billion and full-year fiscal 2027 net sales to $65.0 billion to $72.0 billion, but the figures are preliminary and unaudited, and a Board review of export-control issues could affect the forecasts and prior-period results.
Q4 fiscal 2026 net sales were $11.1 billion versus $5.8 billion in Q4 fiscal 2025; diluted EPS was $1.62 versus $0.31.
Fiscal 2026 net sales were $39.1 billion versus $22.0 billion; diluted EPS was $3.26 versus $1.68.
Outlook: Q1 fiscal 2027 net sales of $14.5 billion to $15.5 billion and GAAP diluted EPS of $0.89 to $0.98; fiscal 2027 net sales of $65.0 billion to $72.0 billion.
The financial results are preliminary and unaudited, and the Board's independent review of export-control matters could affect forecasts and prior period results.
Absci reported second-quarter 2026 results with revenue of $0.3 million, down from $0.6 million a year earlier, and a net loss of $33.2 million, up from $30.6 million. The company said its cash, cash equivalents, and marketable securities of $201.1 million, which include $93.6 million of net offering proceeds, are now expected to fund operations into the second half of 2028, which lessens near-term funding pressure for shareholders.
Revenue was $0.3 million for the quarter ended June 30, 2026, compared with $0.6 million a year earlier.
Net loss was $33.2 million, or $0.21 per share, compared with $30.6 million, or $0.24 per share, a year earlier.
Completed a $100 million underwritten offering that included a $40 million strategic equity investment from Eli Lilly & Company.
Cash and marketable securities were $201.1 million as of June 30, 2026, versus $125.7 million as of March 31, 2026.
Nasdaq notified Rocket One on August 6, 2026 that its common stock no longer meets the $1.00 minimum bid price, and the company has until February 2, 2027 to regain compliance. The stock continues to trade as RKTO for now, but failure to regain compliance could eventually lead to a Nasdaq delisting determination that the company could appeal. Separately, the company said it was accepted into the Seagate Partner Program, which the filing says does not by itself make it an authorized Seagate reseller.
On August 6, 2026, Nasdaq said the stock failed the $1.00 minimum bid price under Rule 5550(a)(2), based on closing bid prices from June 24 to August 5, 2026.
The notice has no immediate effect; the stock continues trading on The Nasdaq Capital Market as RKTO.
Compliance deadline is February 2, 2027 (180 calendar days), requiring a closing bid of at least $1.00 for 10 consecutive business days.
On August 11, 2026, the company announced acceptance into the Seagate Partner Program, which gives access to partner resources and tools.
IZEA Worldwide reported second-quarter 2026 results with revenue of $5.8 million, down 36% from $9.1 million a year earlier, and a net loss of $0.7 million, or $(0.04) per share, compared with net income of $1.2 million, or $0.07 per share, in Q2 2025. The company attributed the decline to its shift toward larger enterprise customers, softer enterprise demand and campaign timing, and said early third-quarter contract commitments have been encouraging.
Revenue was $5.8 million, down $3.3 million (36%) from $9.1 million in Q2 2025
Managed Services bookings fell 19% to $4.5 million
Net loss of $0.7 million, or $(0.04) per share, versus net income of $1.2 million, or $0.07 per share, a year earlier
Cash and equivalents were $46.6 million as of June 30, 2026, with no long-term debt
Bolt Biotherapeutics reported second-quarter 2026 collaboration revenue of $5,000, down from $1.8 million a year earlier, while its net loss narrowed to $7.7 million from $8.6 million on lower research and general and administrative expenses. Cash, cash equivalents and marketable securities were $18.1 million at June 30, 2026, which the company expects to fund operations into the first quarter of 2027, and it said initial clinical data for its lead candidate BDC-4182 is expected with third-quarter 2026 results.
Collaboration revenue was $5,000 for Q2 2026, versus $1.8 million in Q2 2025
Net loss was $7.7 million, or $4.57 per share, versus $8.6 million, or $4.46 per share, a year earlier
Cash and marketable securities of $18.1 million as of June 30, 2026, expected to fund operations into 1Q 2027
Initial BDC-4182 clinical data expected with 3Q 2026 results; the rest of the pipeline is on hold
Achieve Life Sciences reported a second-quarter 2026 net loss of $74.8 million, up from $12.7 million a year earlier, with no revenue reported. The loss includes a non-cash $48.7 million charge tied to the change in fair value of warrant liabilities from its private placement, and the company said it plans to resubmit its cytisinicline NDA in the fourth quarter of 2026 after a June 20, 2026 Complete Response Letter from the FDA.
Q2 2026 net loss was $74.8 million, or $0.80 per share, versus a net loss of $12.7 million, or $0.37 per share, in Q2 2025.
The quarter includes a non-cash $48.7 million charge related to changes in the fair value of warrant liabilities from the private placement.
Total operating expenses were $18.4 million versus $12.6 million a year earlier; cash, cash equivalents and marketable securities were $187.3 million as of June 30, 2026.
On June 20, 2026, the FDA issued a Complete Response Letter; the company plans NDA resubmission in Q4 2026 and anticipates potential approval in the first half of 2027.
Smart Sand reported second-quarter 2026 revenue of $115.1 million, up from $93.1 million in the first quarter and $85.8 million a year earlier, and said it expects 2026 sales volumes to rise 10% to 20% from 2025. Net income was $10.2 million, down from $21.4 million a year earlier but up from a $3.9 million loss in the first quarter. The company also said CFO Lee Beckelman will step down effective January 1, 2027, with General Counsel James Young named as his successor; Young's compensation has not yet been determined.
Q2 2026 revenue was $115.1 million, versus $93.1 million in Q1 2026 and $85.8 million in Q2 2025.
Q2 2026 net income was $10.2 million, or $0.26 per basic share, versus $21.4 million, or $0.55 per basic share, in Q2 2025.
Adjusted EBITDA was $18.7 million, and free cash flow was $(1.4) million in Q2 2026.
Lee Beckelman will leave the CFO role effective January 1, 2027; James Young, currently General Counsel, is named successor, and Beckelman will remain as an advisor through May 31, 2030.
Mereo BioPharma reported second-quarter 2026 results with a net loss of $7.0 million, down from $14.6 million a year earlier, and revenue of zero versus $0.5 million in the prior-year quarter. The company also signed an option and license agreement with Sentynl Therapeutics for alvelestat, and said its cash of $30.1 million should fund operations into late 2027, while setrusumab's Phase 3 studies missed their primary endpoints.
Q2 2026 net loss was $7.0 million, compared with $14.6 million in Q2 2025; revenue was zero versus $0.5 million a year earlier.
Cash and cash equivalents were $30.1 million at June 30, 2026, down from $41.0 million at December 31, 2025, and are expected to fund operations into late 2027.
Sentynl can exercise an option to license alvelestat; on exercise Mereo would be eligible for $40 million in upfront and R&D payments and up to $435 million in milestones.
Orbit and Cosmic Phase 3 studies of setrusumab did not meet the primary fracture-rate endpoints; Mereo and Ultragenyx expect a regulatory path update by year-end 2026.
TON Strategy reported second-quarter 2026 revenue of $15.0 million, up from $3.0 million in the first quarter, driven by Gram staking rewards after the TON Catchain 2.0 upgrade. Net income attributable to the company was $76.8 million, largely due to an $82.8 million noncash gain from changes in the fair value of its Gram holdings, and the company also recorded a $5.5 million noncash stock compensation charge and about $2.9 million of noncash Kingsway advisory-agreement expense. Shareholders see higher revenue and operating income, but the profit figure depends heavily on Gram's market price, and cash and restricted cash fell to $29.0 million.
Total revenue was $15.0 million in Q2 2026 versus $3.0 million in Q1 2026.
Net income attributable to TON Strategy was $76.8 million, including an $82.8 million net gain from Gram fair value changes.
Operating income from continuing operations was $0.5 million, compared with an operating loss of $3.7 million in Q1 2026, despite a $5.5 million noncash charge and about $2.9 million of Kingsway-related noncash expense.
Held about 230.5 million Gram at June 30, 2026; cash and restricted cash was $29.0 million and the company had no debt.
Enviri reported a second-quarter 2026 GAAP loss from continuing operations of $297 million, or $10.70 per diluted share, driven by charges for exiting two European Harsco Rail ETO contracts and transaction-related items tied to the Clean Earth sale and spin-off. Adjusted EBITDA rose to $34 million from $27 million, and the company reaffirmed its 2026 Adjusted EBITDA outlook for Harsco Environmental and Harsco Rail.
GAAP loss from continuing operations was $297 million, or $10.70 per diluted share, versus a loss of $45 million, or $1.70 per share, in Q2 2025.
Adjusted EBITDA was $34 million, up from $27 million a year earlier; adjusted diluted loss per share was $0.63, compared with $0.84.
Reported revenues were $187 million, down from $316 million, but $324 million excluding the Rail contract exit adjustments, a 2% increase.
The company reaffirmed 2026 Adjusted EBITDA guidance of $170 million to $180 million for Harsco Environmental and $(26) million to $(19) million for Harsco Rail.
Mereo BioPharma entered into an Option and License Agreement with Sentynl Therapeutics on August 11, 2026, covering U.S. commercial rights and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo keeps rest-of-world rights and will lead the global Phase 3 study, with the companies refining the study design during the option period. For shareholders, the deal provides for a non-refundable option fee and, on option exercise, $40 million in upfront and R&D payments plus up to $435 million in potential milestones and double-digit tiered royalties on U.S. sales, though these payments depend on Sentynl exercising the option.
Sentynl gets the option to license U.S. commercialization of alvelestat; Mereo keeps rest-of-world rights and leads global Phase 3 development
On option exercise, Mereo is eligible to receive $40 million in upfront and R&D payments
Mereo is also eligible for up to $435 million in potential milestones and double-digit tiered royalties on U.S. sales
The agreement is dated August 11, 2026; the full agreement is expected to be filed with the 10-Q for the quarter ending September 30, 2026
Neuronetics reported second-quarter 2026 revenue of $41.6 million, up 9.1% from a year earlier, driven by Greenbrook clinic revenue. Net loss narrowed to $3.4 million from $10.1 million, but the company trimmed the top end of its full-year 2026 revenue guidance and appointed a new chief financial officer.
Total revenue $41.6 million, up 9.1%; Greenbrook revenue $26.9 million, up 16.8%
Net loss $3.4 million, or $0.05 per share, versus $10.1 million, or $0.15 per share, a year earlier
FY2026 revenue guidance $160 million to $164 million, versus prior $160 million to $166 million
Nir Naor appointed Executive Vice President and Chief Financial Officer
Bicara Therapeutics said Ryan Cohlhepp, its President and Chief Operating Officer, will succeed Claire Mazumdar as Chief Executive Officer effective January 1, 2027, and Jenn Larson will become Chief Financial Officer effective August 12, 2026. The company also reported a second quarter 2026 net loss of $55.4 million, up from $27.4 million a year earlier, while cash, cash equivalents and marketable securities rose to $497.3 million.
Ryan Cohlhepp will become CEO effective January 1, 2027; Claire Mazumdar will become Vice Chair of the Board and Strategic Advisor.
Jenn Larson, CPA, appointed Chief Financial Officer effective August 12, 2026, succeeding Ivan Hyep.
Q2 2026 net loss was $55.4 million versus $27.4 million in Q2 2025; R&D expenses were $45.8 million versus $24.8 million.
Cash, cash equivalents and marketable securities were $497.3 million at June 30, 2026, which the company expects to fund operations into the first half of 2029.
Autolus reported second-quarter 2026 AUCATZYL net product revenue of $45.7 million, up from $20.9 million a year earlier, and raised its full-year 2026 AUCATZYL revenue guidance to $140 million to $150 million from $120 million to $135 million. Net loss narrowed to $39.1 million from $47.9 million, and the company said its cash runway now extends into Q2 2028 after a credit facility draw.
Q2 2026 net product revenue was $45.7 million, versus $20.9 million in Q2 2025 and $26.2 million in Q1 2026.
Gross margin was 55% in Q2 2026, up from 6% in Q1 2026 and negative in all 2025 quarters.
Net loss was $39.1 million, or $(0.15) per share, compared with $47.9 million, or $(0.18) per share, a year earlier.
Cash, cash equivalents and marketable securities were $201.6 million at June 30, 2026, versus $229.4 million at March 31, 2026.
Aura Biosciences reported a second-quarter 2026 net loss of $45.6 million, up from $27.0 million a year earlier, and announced a restructuring that includes a workforce reduction of approximately 20% and a minimal shift of resources away from its bladder cancer program. The company estimates restructuring costs of $2.9 million to $3.2 million and says its cash runway now extends into the first half of 2029, but its chief financial and business officer is departing, which adds leadership change to a wider loss.
Q2 2026 net loss was $45.6 million, versus $27.0 million in Q2 2025; R&D expenses rose to $30.7 million and G&A to $17.3 million, including $10.3 million of stock-based compensation.
Workforce reduction of approximately 20%; estimated restructuring costs of $2.9 million to $3.2 million, with most expected to be paid in Q3 2026.
Cash, cash equivalents and marketable securities totaled $323.8 million as of June 30, 2026, which the company says funds operations into 1H 2029.
Anthony Gibney, Chief Financial and Business Officer, departs effective September 1, 2026; Susan Abu-Absi began as Chief Operating Officer on August 10, 2026.
Xtant Medical reported a second-quarter 2026 net loss of $9.4 million, compared with net income of $3.6 million a year earlier, as revenue fell to $23.0 million from $35.4 million. The company also lowered its full-year 2026 revenue guidance to $99 million to $103 million from $101 million to $105 million, citing lower-than-expected biologics revenue and amnio product headwinds.
Q2 2026 total revenue was $23.0 million versus $35.4 million in Q2 2025; gross margin was 57.9% versus 68.6%.
Q2 2026 net loss was $9.4 million; non-GAAP adjusted EBITDA loss was $2.7 million versus positive $6.9 million a year earlier.
Full-year 2026 revenue guidance was cut to $99 million to $103 million from $101 million to $105 million.
A $5.0 million exclusivity fee paid to Dilon Technologies for a U.S. distribution agreement was written off in the quarter; cash was $9.9 million as of June 30, 2026.
908 Devices reported second-quarter 2026 revenue of $16.1 million, up 23% from a year earlier, and narrowed its net loss from continuing operations to $11.9 million from $12.9 million. The company raised the low end of its full-year 2026 revenue guidance to $68.0 million to $70.0 million, which represents 21% to 25% growth over 2025 revenue. Cash, cash equivalents and marketable securities were $101.5 million at June 30, 2026, with no debt outstanding.
Q2 2026 revenue was $16.1 million, up 23% year over year; recurring revenue was $4.9 million, or 31% of total revenue.
Adjusted EBITDA loss narrowed to $1.9 million from $3.9 million a year earlier.
2026 revenue guidance now $68.0 million to $70.0 million, up from $67.0 million to $70.0 million at the low end.
Cash position of $101.5 million at June 30, 2026, with no debt outstanding.
Vestis reported fiscal third-quarter 2026 revenue of $661.7 million, down 1.8% from the prior year, while net income rose to $11.0 million, or $0.08 per diluted share, from a net loss of $0.7 million. The company raised its fiscal 2026 free cash flow outlook to $160.0 million to $170.0 million, which shareholders can weigh against the unchanged revenue outlook of flat to down 2%.
Q3 revenue was $661.7 million, down $12.1 million or 1.8% from $673.8 million; pounds processed fell 4.5%.
Q3 net income was $11.0 million, or $0.08 per diluted share, versus a net loss of $0.7 million a year earlier; Adjusted EBITDA was $80.9 million versus $64.0 million.
Fiscal 2026 free cash flow outlook raised to $160.0 million to $170.0 million from $120.0 million to $150.0 million; Adjusted EBITDA outlook of $310.0 million to $315.0 million, midpoint up $2.5 million to $312.5 million.
Available liquidity was $351.8 million at July 3, 2026, after the company repaid $30.0 million of debt in the quarter.
Middleby reported second-quarter 2026 net sales of $876 million, up 9.9%, and adjusted EBITDA of $193 million, up from $182 million a year earlier. GAAP diluted EPS from continuing operations fell to $1.20 from $1.91, which the filing ties to a $28.9 million equity loss from an affiliate and $14 million of strategic transaction costs, while adjusted EPS rose to $2.35 from $2.20. The company said it raised its full-year 2026 guidance after completing the Food Processing spin-off on July 6, 2026.
Q2 2026 net sales of $875.5 million, up 9.9% (6.4% organic); Commercial Foodservice organic growth of 8.3%
Diluted GAAP EPS from continuing operations of $1.20 versus $1.91; adjusted EPS of $2.35 versus $2.20
Full-year 2026 adjusted EPS guidance of $6.73-$6.89 and net sales of $2.48-$2.53 billion, excluding Food Processing and Residential
Company repurchased 1.4 million shares in Q2 2026 and 3.8 million shares year to date
Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier, and raised its full-year 2026 revenue growth guidance to 3% to 5%. The company's GAAP net loss widened to $2.9 million from $2.3 million, so the sales gain came with a larger loss for shareholders.
Q2 2026 revenue of $22.7 million vs. $20.5 million in Q2 2025; foreign currency added about 1%
Q2 2026 net loss of $2.9 million vs. $2.3 million in Q2 2025; adjusted EBITDA rose to $1.7 million from $1.5 million
Full-year 2026 revenue growth guidance raised to 3% to 5%; adjusted gross margin target lowered to 57% to 59%
Third quarter 2026 revenue guidance of $21.0 million to $22.6 million
Broadwind reported second quarter 2026 revenue of $24.3 million, up 67% from a year earlier, and a loss from continuing operations of $0.7 million ($0.03 per share), down from $3.0 million ($0.13 per share). The results follow the company's exit from wind fabrications through the sale of its Abilene, Texas facility for up to $19.5 million, which the company says is a strategic move toward precision manufacturing.
Revenue of $24.3 million versus $14.5 million in Q2 2025; total orders of $35.2 million, up 68%
Loss from continuing operations of $0.7 million ($0.03 per share) versus $3.0 million ($0.13 per share) a year earlier
Non-GAAP Adjusted EBITDA of $1.6 million versus a loss of $1.1 million in Q2 2025
Abilene, Texas facility sold to IES Infrastructure for up to $19.5 million under an agreement dated April 30, 2026; liquidity at June 30, 2026 was $40.1 million
Janus International reported second-quarter 2026 revenue of $233.5 million, up 2.4% year over year, while net income fell to $10.7 million from $20.7 million and adjusted EBITDA fell 18.0% to $40.2 million. The company also updated its full-year 2026 outlook, with total revenue guided to $925 million to $945 million and adjusted EBITDA to $150 million to $170 million, and the CEO said results came in slightly below company expectations.
Net income was $10.7 million, or $0.08 per diluted share, versus $20.7 million, or $0.15, a year earlier.
Adjusted EBITDA was $40.2 million, down 18.0%, with an adjusted EBITDA margin of 17.2%, down about 430 basis points.
Full-year 2026 guidance: total revenue of $925 million to $945 million and adjusted EBITDA of $150 million to $170 million.
Nokē Smart Entry System installed units reached 501,000 at quarter end, up 22.5% year over year.
IES Holdings agreed on August 7, 2026 to acquire about 92% of DBM Global, a structural steel fabrication and erection company, from INNOVATE Corp. The base purchase price is $650 million, paid partly in 215,487 IES shares valued at $140 million and partly in cash, and the deal would add a new Structural business line. Closing is expected in the quarter ending December 31, 2026, subject to regulatory approvals, and the new IES shares would add to the share count.
Base purchase price of $650 million, subject to customary adjustments; seller receives 215,487 IES shares ($140 million at $649.69 per share) plus cash
DBM Global generated revenue of approximately $1.3 billion for the twelve months ended March 31, 2026 and employs about 3,400 people
Expected to close in the quarter ending December 31, 2026; outside date February 7, 2027; no termination fee payable by either party
Stock consideration shares were sold in a private placement and are subject to a lock-up ending the earlier of 60 days after closing or effectiveness of a resale registration statement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.